Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Why ViroPharma Shares Soared

Don't let it get away!

Keep track of the stocks that matter to you.

Help yourself with the Fool's FREE and easy new watchlist service today.

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of biotechnology company ViroPharma (Nasdaq: VPHM  ) soared as much as 16% today after the company received supplemental approval to Cinryze's Biologics License Applications from the Food and Drug Administration for industrial scale manufacturing changes.

So what: The ruling today is important because it allows ViroPharma to adequately ramp up Cinryze production, with the relabeling process of previously produced vials only expected to take six weeks.

Now what: Today's FDA ruling is also important because ViroPharma has been in a world of hurt since the FDA ruled against it in allowing generic competition to enter the market to compete against its previous blockbuster, Vancocin. Since that ruling, both Akorn (Nasdaq: AKRX  ) and Watson Pharmaceuticals (NYSE: WPI  ) have entered the market with generic versions of the drug. Therefore, Cinryze is ViroPharma's new horse in the race, and today's actions allow it to greatly increase production and potentially profits. I'm still not sold on ViroPharma given the huge windfall it took with Vancocin's loss, but this is definitely a step in the right direction.

Craving more input? Start by adding ViroPharma to your free and personalized Watchlist so you can keep up on the latest news with the company.

Fool contributor Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1974154, ~/Articles/ArticleHandler.aspx, 10/28/2016 11:50:59 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,231.35 61.67 0.34%
S&P 500 2,138.31 5.27 0.25%
NASD 5,224.05 8.08 0.15%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

12/31/1969 7:00 PM
VPHM.DL $0.00 Down +0.00 +0.00%
ViroPharma CAPS Rating: ***
AGN $214.08 Down -7.44 -3.36%
Allergan CAPS Rating: ****
AKRX $24.10 Down -0.68 -2.74%
Akorn CAPS Rating: ***